Systemic sclerosis-associated pulmonary hypertension: Why disease-specific composite endpoints are needed

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  Denton, Christopher P ^a   Avouac, Jerome ^b   Behrens, Frank ^c   Furst, Daniel E ^d   Foeldvari, Ivan ^e   Humbert, Marc ^f   Huscher, Doerte ^g   Kowal Bielecka, Otylia ^h   Matucci Cerinic, Marco ⁱ   Nash, Peter ^j   Opitz, Christian F ^k   Pittrow, David ^l   Rubin, Lewis J ^m   Seibold, James R ⁿ   Distler, Oliver ^o  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b RDU   (France)

^c German Rheumatism Research Centre   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e General Hospital   (Germany)

^f HÔPITAL ANTOINE BÉCLÈRE   (France)

^g GOETHE UNIVERSITY   (Germany)

^h MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

ⁱ UNIVERSITY OF FLORENCE   (Italy)

^j Rheumatology Research Unit   (Australia)

^k German Red Cross Hospital   (Germany)

^l DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ Scleroderma Research Consultants   (United States)

^o UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOPPLER ECHOCARDIOGRAPHY; DYSPNEA; ECHOCARDIOGRAPHY; EXERCISE TEST; HEART CATHETERIZATION; HEART FUNCTION; HUMAN; LUNG VASCULAR RESISTANCE; MORTALITY; NOTE; OUTCOME ASSESSMENT; OUTPATIENT CARE; PULMONARY HYPERTENSION; PULMONOLOGY; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; SURVIVAL; SYSTEMIC SCLEROSIS; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFECT; EXERCISE TOLERANCE; HEART FUNCTION TEST; HOSPITALIZATION; LUNG FUNCTION TEST; METHODOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; EXERCISE TOLERANCE; HEART FUNCTION TESTS; HUMANS; HYPERTENSION, PULMONARY; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84855698938     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3346     Document Type: Note

References (16)

1. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43(12 Suppl S):5S-12S.
2. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54(1 Suppl):S43-54.
3. Kabunga P, Coghlan G. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma. Drugs 2008, 68:1635-1645. 10.2165/00003495-200868120-00003, 18681488.
4. Macchia A, Marchioli R, Marfi si R, Scarano M, Levantesi G, Tavazzi L, Tognoni G. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007, 153:1037-1047. 10.1016/j.ahj.2007.02.037, 17540207.
5. Furst D, Khanna D, Matucci-Cerinic M, Clements P, Steen V, Pope J, Merkel P, Foeldvari I, Seibold J, Pittrow D, Polisson R, Strand V. Systemic sclerosis - continuing progress in developing clinical measures of response. J Rheumatol 2007, 34:1194-1200.
6. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Furst DE, . EPOSS-Omeract Group Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum 2008, 59:867-875. 10.1002/art.23718, 18512721, EPOSS-Omeract Group.
7. Sánchez-Román J, Opitz CF, Kowal-Bielecka O, García-Hernández FJ, Castillo-Palma MJ, Pittrow D, . EPOSS-OMERACT Group Screening for PAH in patients with systemic sclerosis: focus on Doppler echocardiography. Rheumatology (Oxford) 2008, 47(Suppl 5):v33-35. EPOSS-OMERACT Group.
8. Huscher D, Pittrow D, Distler O, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Kowal-Bielecka O, Avouac J, Behrens F, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, . EPOSS-OMERACT Group Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Clin Exp Rheumatol 2010, 28(2 Suppl 58):S47-52. EPOSS-OMERACT Group.
9. Avouac J, Kowal-Bielecka O, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Distler O, Furst DE, . EPOSS Group Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Ann Rheum Dis 2010, 69:1360-1363. EPOSS Group.
10. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O, . EPOSS Group Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol 2010, 37:105-115. 10.3899/jrheum.090661, 19955042, EPOSS Group.
11. Khanna D, Distler O, Avouac J, Behrens F, Clements PJ, Denton C, Foeldvari I, Giannini E, Huscher D, Kowal-Bielecka O, Lovell D, Matucci-Cerinic M, Mayes M, Merkel PA, Nash P, Opitz CF, Pittrow D, Rubin L, Seibold JR, Steen V, Strand CV, Tugwell PS, Varga J, Zink A, Furst DE, . CRISS; EPOSS Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol 2009, 36:2356-2361. 10.3899/jrheum.090372, 19820225, CRISS; EPOSS.
12. Pittrow D, Ghofrani HA, Opitz CF, Huscher D, Hoeper MM. International, prospective register for the documentation of first-line and maintenance therapy in patients with pulmonary hypertension (CompERA-XL)]. Dtsch Med Wochenschr 2009, 134(Suppl 5):S173-175.
13. Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, Mouthon L, Hatron PY, Jego P, Allanore Y, Tiev KP, Agard C, Cosnes A, Cirstea D, Constans J, Farge D, Viallard JF, Harle JR, Patat F, Imbert B, Kahan A, Cabane J, Clerson P, Guillevin L, Humbert M. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009, 60:1831-1839. 10.1002/art.24525, 19479881.
14. de Oliveira NC, dos Santos Sabbag LM, Ueno LM, de Souza RB, Borges CL, de Sá Pinto AL, Lima FR. Reduced exercise capacity in systemic sclerosis patients without pulmonary involvement. Scand J Rheumatol 2007, 36:458-4561. 10.1080/03009740701605889, 18092268.
15. Buch MH, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells AU, Matucci-Cerinic M, Riemekasten G, Emery P, Chadha-Boreham H, Charef P, Roux S, Black CM, Seibold JR. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis 2007, 66:169-173. 1798506, 16868020.
16. McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galiè N, Gibbs JS, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54(1 Suppl):S97-107.